MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Feasibility of using mobile technology for aerobic exercise management in people with Parkinson’s disease

    MKY. Mak, LJ. Ren, ISK. Wong-Yu (Hong Kong SAR, China)

    Objective: To examine the usability of a smartwatch heart rate monitor for monitoring aerobic exercise compliance during a 6-month brisk walking program, and to evaluate…
  • 2022 International Congress

    SelfCog®: a digitized cognitive battery to classify Parkinson disease (PD) patients with or without Mild Cognitive Impairment (MCI)

    J. Montillot, R. Massart, K. Hernandez, M. Lunven, G. Fénelon, H. Salhi, A. Bachoud-Lévi, P. Rémy (Créteil, France)

    Objective: We tested the performance of the SelfCog® to classify PD patients as MCI. Background: MCI is a strong risk factor of dementia in PD…
  • 2022 International Congress

    Genetics Of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) : Genetics of Juvenile, Young and Early Onset Parkinson’s Disease

    P. Kukkle, V. Goyal, T. Geetha, R. Menon, R. Kandadai, U. Mahadevia, H. Kumar, R. Borgohain, A. Mukherjee, P. Wadia, R. Yadav, S. Desai, N. Kumar, S. Nair, S. Murugan, A. Biswas, P. Pal, M. Oliver, S. Sundaram, M. Deshmukh, A. Bassi, C. Sandeep, N. Mandloi, A. Kayalvizhi, U. Muthane, S. Das, S. Seshagiri, R. Gupta, V. Ramprasad (Bangalore, India)

    Objective: To determine the genetic and demographic patterns of juvenile-onset (JOPD, <20 years), young-onset (YOPD, 20-40 years), and early onset (EOPD, 40-50 years) Parkinson's disease…
  • 2022 International Congress

    Clinical characteristics in de-novo PD patients with reversible vs. progressive cognitive dysfunction during long-term follow-up

    K. Kawabata, A. Djamshidian-Tehrani, K. Seppi, W. Poewe (Innsbruck, Austria)

    Objective: To compare clinical and imaging features in de-novo Parkinson’s disease (PD) with stable, remitting, and non-remitting cognition over 5 years follow-up. Background: Mild cognitive…
  • 2022 International Congress

    The Lion’s tail family: A Bavarian multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia

    A. Fanciulli, F. Leys, F. Lehner, V. Sidoroff, V. Ruf, C. Raccagni, P. Mahlknecht, D. Kuipers, W. van Ijcken, H. Stockner, T. Musacchio, J. Volkmann, C. Monoranu, I. Stankovic, G. Breedveld, F. Ferraro, C. Fevga, O. Windl, J. Herms, S. Kiechl, W. Poewe, K. Seppi, N. Stefanova, S. Scholz, V. Bonifati, G. Wenning (Innsbruck, Austria)

    Objective: To characterize a North-Bavarian (Lion’s tail region) six-generation pedigree, including neuropathologically confirmed multiple system atrophy and Parkinson’s disease with dementia. Background: Multiple system atrophy…
  • 2022 International Congress

    Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients

    D. Mcintyre, O. Terwindt, L. Pavelka, G. Schilling, A. Znati, L. Skhiri, M. Gantenbein, E. Heller, A. Heller, J. Kennedy, J. Harmon, C. Kamp, M. Torti, CW. Olanow, R. Krueger (Strassen, Luxembourg)

    Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of a novel continuous levodopa-carbidopa oral pump (LCOP) delivery system in patients with early PD. Background:…
  • 2022 International Congress

    The relationship between sleep and Parkinson’s disease progression: A Mendelian Randomization study

    E. Matar, M. Mahjoub (Sydney, Australia)

    Objective: The objective of the study was to determine the causality between sleep disorders and progression of motor and cognitive endpoints of Parkinson’s disease. Background:…
  • 2022 International Congress

    CCL5 promotes Th17 migrating into SNpc by promoting Th17 proportion increase and LFA-1 expression

    XZ. Xue (WuHan, China)

    Objective: To explore the specific pathway by which CCL5 induces Th17 cells migrating into substantia nigra pars compacta (SNpc) to aggravate Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Blood-derived α-synuclein from Parkinson´s disease patients is able to seed pathology

    A. Kluge, J. Bunk, E. Schäffer, H. Knacke, A. Drobny, W. Xiang, R. Lucius, P. Arnold, F. Zunke, D. Berg (Kiel, Germany)

    Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients. Background: PD pathology is…
  • 2022 International Congress

    Characteristics and Techniques to Improve Micrographia in Parkinson’s Disease

    S. Shahid (Southampton, USA)

    Objective: To analyze and identify the characteristics found in micrographia and provide methods of improving the symptom. Background: Micrographia, also known as small handwriting, is…
  • « Previous Page
  • 1
  • …
  • 357
  • 358
  • 359
  • 360
  • 361
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley